Form 8-K - Current report:
SEC Accession No. 0000950170-25-079689
Filing Date
2025-05-30
Accepted
2025-05-30 16:05:12
Documents
11
Period of Report
2025-05-30
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K clsd-20250530.htm   iXBRL 8-K 89136
2 EX-3.1 clsd-ex3_1.htm EX-3.1 16239
  Complete submission text file 0000950170-25-079689.txt   218888

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT clsd-20250530.xsd EX-101.SCH 25824
13 EXTRACTED XBRL INSTANCE DOCUMENT clsd-20250530_htm.xml XML 4900
Mailing Address 900 NORTH POINT PARKWAY SUITE 200 ALPHARETTA GA 30005
Business Address 900 NORTH POINT PARKWAY SUITE 200 ALPHARETTA GA 30005 678-270-3631
Clearside Biomedical, Inc. (Filer) CIK: 0001539029 (see all company filings)

EIN.: 452437375 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37783 | Film No.: 251010783
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)